A fixed-dose combination (FDC) tablet containing Tadalafil, a long-acting phosphodiesterase type 5 (PDE5) inhibitor for erectile dysfunction (ED), and Dapoxetine, a short-acting selective serotonin reuptake inhibitor (SSRI) for premature ejaculation (PE). This combination is specifically indicated for men with comorbid ED and PE, addressing both conditions simultaneously. It is a prescription-only medicine in India.
Adult: One tablet (Tadalafil 10mg + Dapoxetine 30mg) taken orally with a full glass of water, approximately 1-3 hours before anticipated sexual activity. Should not be taken more than once in 24 hours.
Note: Take on an empty stomach or with a light meal for optimal and predictable effect. A high-fat meal may delay the absorption of tadalafil. Tablet should be swallowed whole, not crushed or chewed. Sexual stimulation is required for tadalafil to be effective.
Tadalafil: Inhibits PDE5 enzyme in the corpus cavernosum of the penis, preventing degradation of cyclic guanosine monophosphate (cGMP). Elevated cGMP leads to smooth muscle relaxation, increased blood flow, and erection in response to sexual stimulation. Dapoxetine: Rapidly inhibits presynaptic serotonin reuptake, increasing serotonin activity in the synaptic cleft within the central nervous system (specifically the hypothalamic nuclei). This is believed to enhance serotonergic tone, increasing intravaginal ejaculatory latency time (IELT) and improving control over ejaculation.
Pregnancy: Not indicated for use in women. Category not assigned.
Driving: May cause dizziness, syncope, or blurred vision. Patients should not drive or operate heavy machinery until they know how the drug affects them, especially after the first dose.
| Organic Nitrates (Nitroglycerin, Isosorbide) | Profound hypotension, risk of myocardial infarction, stroke, or death. | Contraindicated |
| Potent CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Ritonavir, Clarithromycin) | Markedly increases plasma levels of tadalafil and dapoxetine, increasing toxicity risk. | Contraindicated |
| Alpha-blockers (Doxazosin, Tamsulosin, Prazosin) | Additive blood pressure lowering, risk of symptomatic hypotension (dizziness, fainting). | Major - Avoid concomitant use. If necessary, initiate alpha-blocker at lowest dose. |
| Other PDE5 Inhibitors (Sildenafil, Vardenafil) | Additive effects, increased risk of side effects. | Major - Do not combine. |
| Other SSRIs/SNRIs/Tricyclics (Fluoxetine, Sertraline, Venlafaxine, Amitriptyline) | Increased risk of serotonin syndrome. | Contraindicated |
| MAO Inhibitors (Phenelzine, Selegiline) | Risk of serotonin syndrome. | Contraindicated |
| Thioridazine | Increased thioridazine levels, risk of QT prolongation. | Contraindicated |
| Moderate CYP3A4 Inhibitors (Erythromycin, Grapefruit Juice) | May increase tadalafil/dapoxetine exposure. Use with caution. | Moderate |
| CYP3A4 Inducers (Rifampicin, Carbamazepine, Phenytoin) | May decrease plasma levels, reducing efficacy. | Moderate |
Same composition (Tadalafil (10mg) + Dapoxetine (30mg)), different brands: